Related Experiment Video
Updated: Sep 22, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
New FDA draft guidance on premarket submissions
1Donawa and Associates, Ltd., Rome, Italy.
Abstract:
The United States Food and Drug Administration (FDA) has issued a draft guidance document on the type of quality system information to be included in various premarket submissions. This is the same information that should be maintained at the manufacturing facility for devices subject to the premarket notification or 510(k) process. This article discusses the contents of the draft guidance and recommends that manufacturers send their comments on the guidance to FDA.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Preclinical Development: Overview
Drug Products: Biologics, Biosimilars and Interchangeables
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
FDA Approved Drugs: Changes to Approved Drugs

